Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

2.
3.
4.

Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.

Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A.

Pediatrics. 1996 Sep;98(3 Pt 1):420-8.

PMID:
8784367
6.

Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.

Buckley RH, Schiff SE, Sampson HA, Schiff RI, Markert ML, Knutsen AP, Hershfield MS, Huang AT, Mickey GH, Ward FE.

J Immunol. 1986 Apr 1;136(7):2398-407.

PMID:
2869085
7.
8.
9.

Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors.

Friedrich W, Goldmann SF, Ebell W, Bl├╝tters-Sawatzki R, Gaedicke G, Raghavachar A, Peter HH, Belohradsky B, Kreth W, Kubanek B, et al.

Eur J Pediatr. 1985 Jul;144(2):125-30.

PMID:
3899661
10.

Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation.

Dror Y, Gallagher R, Wara DW, Colombe BW, Merino A, Benkerrou M, Cowan MJ.

Blood. 1993 Apr 15;81(8):2021-30.

11.

In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.

Kohler PC, Erickson C, Finlay JL, Trigg ME, Edwards B, Hong R, Hank JA, Billing R, Bozdech M, Sondel PM.

Cancer Res. 1986 Oct;46(10):5413-8.

12.

Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.

Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J, et al.

Ann Intern Med. 1986 Jul;105(1):20-6.

PMID:
3521427
13.

Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders.

Knutsen AP, Wall DA.

J Allergy Clin Immunol. 1999 May;103(5 Pt 1):823-32.

PMID:
10329816
14.

Thymus and B cell reconstitution in severe combined immunodeficiency after transplantation of monoclonal antibody depleted parental mismatched bone marrow.

Hong R, Horowitz S, Moen R, Trigg M, Sondel P, Billing R, Borcherding W, Johnson JP, Kanoff M, Bias WB, et al.

Bone Marrow Transplant. 1987 Apr;1(4):405-9.

PMID:
3332148
15.

[Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].

Ji SQ, Chen HR, Wang HX, Yan HM, Liu J, Xue M, Zhu L.

Zhonghua Xue Ye Xue Za Zhi. 2003 Aug;24(8):416-9. Chinese.

PMID:
14642179
16.

CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.

Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.

Biol Blood Marrow Transplant. 1997 Apr;3(1):11-7.

PMID:
9209736
18.

Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.

Trigg ME, Billing R, Sondel PM, Exten R, Hong R, Bozdech MJ, Horowitz SD, Finlay JL, Moen R, Longo W, et al.

Cancer Treat Rep. 1985 Apr;69(4):377-86.

PMID:
3888387
19.
20.

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.

Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.

Biol Blood Marrow Transplant. 2000;6(3A):309-20.

PMID:
10905768

Supplemental Content

Support Center